SRPT

Sarepta Therapeutics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 0/10
  • Value↓ 2/10
Sarepta Therapeutics sales and earnings growth
SRPT Growth
Low
  • Revenue Y/Y↑ 15.58%
  • EPS Y/Y↓ -388.66%
  • FCF Y/Y↑ 10.61%
Sarepta Therapeutics gross and profit margin trends
SRPT Profitability
Neutral
  • Gross margin ↑ 61.80%
  • EPS margin↓ -32.50%
  • ROIC 5Y↓ -10.19%
Sarepta Therapeutics net debt vs free cash flow
SRPT Risk
Great
  • Debt / Equity↓ 0.9
  • Debt / FCF↓ 0.7
  • Interest coverage↑ 999.0

Sarepta Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗